Patent intelligence · US
US 7101863
Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
Patent details — US 7101863
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 5, 2006
- Expiration
- Aug 31, 2026
- Applicant
- BIODEX
- Claims
- 11
- CPC classes
- A61K, A61K31/721, A61P, A61P1/04
Quick answer
US 7101863 (Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative) is held by BIODEX. Status: granted. Granted Sep 5, 2006. Expires Aug 31, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIODEX
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/721, A61P, A61P1/04, A61P17/00, A61P17/02
More from BIODEX
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 7101863?
US 7101863 (Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative) is held by BIODEX. Status: granted. Granted Sep 5, 2006. Expires Aug 31, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7101863?
BIODEX is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 7101863 expire?
Our index shows an expiration date of Aug 31, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.